Form 4: Zeo ScientifiX Insider Option Grant Disclosure

Wendy Grey and Greyt Ventures, LLC were granted a total of 1.25 million stock options in Zeo ScientifiX, Inc. on June 10, 2026.

Summary

• Wendy Grey and Greyt Ventures, LLC, a 10% owner and consultant, received two separate grants of 625,000 stock options each.
• The options have an exercise price of $1.67 per share.
• One tranche of 625,000 options vested immediately upon the grant date of June 10, 2026.
• The second tranche of 625,000 options vests upon the achievement of specific performance milestones.
• All options expire on June 10, 2036, and are exercisable on a cashless basis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative disclosure regarding insider compensation that does not fundamentally alter the company's current financial position.

Positives

• The grant aligns the interests of a major shareholder and consultant with the long-term performance of the company.
• The performance-based vesting criteria for half of the options incentivizes the achievement of specific corporate milestones.

Negatives

• The issuance of 1.25 million options creates potential future dilution for existing shareholders.
• The options include anti-dilution provisions that protect the holder in the event of future large-scale equity issuances.

Risks

• Potential dilution of existing shareholder equity upon the exercise of the 1.25 million options.
• The anti-dilution clause may complicate future capital raising efforts by triggering adjustments for issuances exceeding 10% of outstanding stock.

Future Outlook

The options are exercisable over a ten-year period, with half contingent on meeting performance milestones, suggesting management's focus on long-term growth targets.

Management Comments

• The options are subject to the terms and conditions of the 2021 Equity Incentive Plan.
• The options are anti-dilutive for any future transaction providing for the issuance of 10% or more of the company's common stock.

Industry Context

StockSavvy.ai notes that equity-based compensation for consultants and major shareholders is common in the biotechnology and scientific research sectors to preserve cash while incentivizing strategic advisory roles.

Comparison to Industry Standards

• The use of performance-based vesting is consistent with standard corporate governance practices for aligning consultant incentives with shareholder value.
• Cashless exercise provisions are standard in equity incentive plans to facilitate liquidity for insiders without requiring immediate capital outlay.

Corporate Governance

Related Party Transactions

• Greyt Ventures, LLC is a principal stockholder and consultant to the issuer, and is owned by a trust for which Wendy Grey is the trustee.

Stakeholder Impact

• Shareholders may face dilution if options are exercised.
• The consultant's alignment with the company's performance milestones may benefit long-term stakeholders.

Next Steps

• Monitoring for the achievement of performance milestones related to the 625,000 performance-vesting options.
• Tracking potential future exercises of these options which would impact share count.

Key Dates

Keywords

Zeo ScientifiX, ZEOX, Form 4, Insider Trading, Stock Options, Equity Incentive Plan, Dilution